# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹295.5 Cr** Q4 Cons. (+9.4%) · **₹1,168.2 Cr** FY26 Cons. (+4.8%) · **₹230.4 Cr** Q4 Standalone (+7.6%) * **EBITDA:** **₹37.4 Cr** Q4 Cons. (+43.1%) · **₹169.6 Cr** FY26 Cons. · **₹37.1 Cr** Q4 Standalone (-1.1%) * **EBITDA Margin:** **12.7%** Q4 Cons. (+300 bps) · **14.5%** FY26 Cons. · **16.1%** Q4 Standalone (-160 bps) * **PAT:** **₹18.5 Cr** Q4 Cons. (vs. Loss) · **₹34.7 Cr** FY26 Cons. (+1,726%) · **₹53.7 Cr** Q4 Standalone (+258%) * **Leverage:** **0.44x** Gearing Ratio · **₹446.2 Cr** Cons. Net Debt · **₹43.8 Cr** Standalone Net Debt ## B. Margins & Profitability * **Profitability Turnaround:** Consolidated bottom-line performance saw a massive recovery from prior-year losses, fueled by robust EBITDA expansion and structural tax benefits. * **Tax Regime Optimization:** Transition to a new tax structure reduced the effective rate from **35% to 25%**, providing immediate P&L relief and expected recurring cash flow benefits from FY27. * **Operational Efficiency:** Margin recovery was supported by COGS optimization, supply chain restructuring, and the strategic closure of two loss-making units in **Rajkot and Lucknow**. * **Standalone Compression:** Despite top-line growth, standalone margins tightened slightly, prompting management to collaborate with clinical staff on cost-optimization measures. ## C. Balance Sheet & Debt Profile * **Debt Drivers:** Current consolidated borrowings are primarily tied to the acquisition of the **D. S. MedTech business** and the **Gurugram unit**. * **Deleveraging Outlook:** Management anticipates an improving debt-to-equity trend as the international MedTech segment has reached breakeven, curbing the need for further capital infusions. * **Working Capital:** While inventory remains elevated to support global scaling, the company achieved a material reduction in **days of inventory**, signaling improved capital efficiency. * **Asset Returns:** The standalone business continues to deliver a steady performance with an annualized ROCE of **10.8%**. ## D. Capital Allocation * **Strategic Reinvestment:** Management signaled high conviction in the international hospital segment by infusing **₹60 Cr** in equity, raising their ownership stake to **91%**. * **MedTech Recovery:** The international business achieved a positive EBITDA of **₹6.7 Cr** for the full year, a significant swing from the **₹19.2 Cr** loss in the previous fiscal. --- # 2. Hospital Operations & Metrics ## A. Key Figures * **ARPOB:** **₹42,689** Group (+2.7%) · **₹88,592** Gurugram Unit * **Occupancy:** **48%** Group · **50%** Group ex-Gurugram · **>50%** FY27 Guidance * **Operational Metrics:** **649** Occupied Beds (+2.4%) · **3.81 Days** ALOS Group · **3.44 Days** ALOS Gurugram * **Gross Margin:** **85%** Q4 (vs. ~90% previous) ## B. Payer & Case Mix * **Revenue Composition:** Payer mix remains balanced between insurance, self-pay, and government business, with international patients contributing nearly half of Gurugram's revenue. * **Clinical Volume:** Group achieved significant clinical scale in FY26, completing **70 total transplants**, including **51 kidney** and **19 liver** procedures. ## C. Operational Recovery & Staffing * **Strategic Recruitment:** Medical staff expanded to **400 doctors** (up from 350) following the hiring of super-specialists to counter previous attrition. * **Margin Compression:** Profitability was temporarily impacted by higher recruitment costs and operational stabilization efforts following mid-year turbulence. * **Unit Stabilization:** PK Health facility has stabilized post-leadership changes, with growth accelerating in orthopedics and ENT alongside new urology and BMT specialists. ## D. Growth Outlook * **Performance Drivers:** Management anticipates occupancy expansion driven by turnaround momentum in the Gurugram, Indore, and Surat units. * **Lagged Financial Impact:** Revenue contributions from the newly onboarded medical teams are expected to materialize starting in the next quarter. --- # 3. MedTech & Implant Segment ## A. Key Figures * **Consolidated Revenue:** **₹40 Cr** Q4 FY'26 (+45% YoY, +32% QoQ) * **Consolidated EBITDA:** **>₹3.7 Cr** Q4 FY'26 (vs. **-₹9.3 Cr** YoY) * **Long-term Target (2030):** **₹600 Cr – ₹700 Cr** Revenue · **15%+** EBITDA Margin ## B. Financial Turnaround * **Operational Inflection:** The segment achieved a significant turnaround, marking its second consecutive quarter of positive EBITDA, driven by robust double-digit top-line growth. * **C. S. Performance:** The domestic U.S. implant business has successfully pivoted to profitability, overcoming previous operational challenges. * **Efficiency Roadmap:** Management is targeting incremental quarter-on-quarter improvements with the goal of reaching **double-digit EBITDA** and positive cash flow. * **Supply Chain Optimization:** Future resilience will be driven by a **China Plus One** multi-vendor sourcing strategy and demand-driven inventory planning. ## C. Product Portfolio & Global Expansion * **Portfolio Focus:** Current offerings are concentrated in knee and hip categories; future R&D will focus on deepening these existing lines rather than horizontal diversification. * **Geographic Scaling:** Beyond established presence in Japan and the U.S., the company is aggressively pursuing regulatory approvals across **Southeast Asia, Latin America, and the Middle East**. * **Strategic Positioning:** The long-term objective is to leverage **India-competitive economics** to provide world-class clinical outcomes on a global scale. ## D. R&D & Innovation * **Clinical Validation:** Investments are being directed toward multicenter clinical studies and registry data to solidify the market position of the **Touch platform**. * **Localized Engineering:** Development of **proprietary sizing libraries** tailored for Asian and emerging market anatomies to differentiate from Western competitors. * **Cost-Intelligent R&D:** Establishing an India-based design hub to leverage local engineering talent and academic collaborations for global product development. --- # 4. Strategic Initiatives ## A. Oncology Expansion * **Infrastructure Scaling:** Aggressive investment in oncology infrastructure via new bunkers in **Surat and Krishna**, complementing existing facilities and recent PET/CT scan technology upgrades. * **Specialized Talent Acquisition:** Recruited super-specialty oncology surgeons for the **Zynova Mumbai** facility to drive high-end surgical volumes despite the lack of a dedicated unit in the city. * **Margin Compression:** Increased focus on oncology treatments has pressured margins due to the high cost of specialized medicines required for patient care. ## B. Franchise & M&A Strategy * **Strategic Pivot:** Management has abandoned the target of **50 franchisee models**, shifting focus back to core hospital operations and the implant business to protect quality standards. * **Rationalization of FOSO:** Revenue from franchise-owned units remains immaterial following the closure of loss-making locations; future franchisee growth will be highly selective. * **Inorganic Growth Framework:** Future expansion will prioritize the acquisition of profitable hospital assets that align with existing bed capacity and cash flow requirements. ## C. Leadership & Training * **Academic Integration:** The Shalby Academy trained over **2,400 participants** in FY '26, launching new BBA/MBA healthcare programs to secure a long-term talent pipeline. * **Clinical Confidence Building:** Domestic growth is being underpinned by cadaveric workshops and clinical education across major hubs to strengthen surgeon loyalty and evidence-based adoption. * **Organizational Depth:** Currently developing a **second layer of leadership** across sales, regulatory, and engineering functions to support institutional stability. ## D. Technology & Robotics * **Robotic Commercialization:** Transitioning the **Curexo robotic partnership** from pilot phase to full commercial adoption in select markets to drive surgical precision. * **Operational Efficiency:** Priorities have shifted toward digital integration and supply chain efficiency to drive operating leverage and maintain strict cash discipline. * **Revenue Conversion:** Recent capital expenditure in robotics and radiation bunkers is already yielding significant revenue, with further upside expected from **TPA renewals**. --- # 5. Geography & Market Mix ## A. Key Figures * Top-line Growth: 5% FY'26 (vs. 15%–16% CAGR FY'23–'25) * **Gurugram Unit Revenue:** **₹21.5 Cr** Q4 FY'26 (-5.7% YoY) * **Group International Revenue:** **₹12.8 Cr** Q4 FY'26 total · **₹9.1 Cr** via Shalby International · **₹3.6 Cr** via Multi-Specialty * **Gurugram Revenue Mix:** **60%** International Patient contribution ## B. Domestic & Regional Performance * **Growth Headwinds:** Recent deceleration in top-line growth attributed to operational turbulence at the Gurugram unit and disruptions in inpatient volumes linked to government schemes. * **Operating Leverage:** Overall financial performance remains supported by strong momentum in the core India business and improved North American subsidiary performance. ## C. International Patient Flow & Recovery * **Geopolitical Impact:** Middle East tensions and the U.S.-Iran conflict caused a slight YoY decline in international revenue, though management views this as a temporary disruption to non-deferrable medical procedures. * **Profitability Path:** The Gurugram unit is nearing EBITDA breakeven, bolstered by a recent **NABH accreditation** in February which enables rate hikes and new TPA renewals. * **Volume Outlook:** A strong recovery in patient volumes was noted in **April and May**, with a significant surgical backlog expected to materialize as regional conflicts stabilize. ## D. Emerging Market Strategy * **Market Diversification:** To offset regional volatility, the group is aggressively expanding its footprint in **Africa and CIS countries**, specifically noting momentum in **Uzbekistan, Kazakhstan, and Sudan**. * **Product Localization:** Growth strategy is centered on developing medical products specifically engineered for emerging market needs rather than adapting Western-centric systems. * **Operational Mitigation:** Increased marketing and cost optimization measures in new territories are successfully compensating for regional disruptions and improving margins. --- # 6. Risks & Healthcare Externalities ## A. Key Figures * **Revenue Upside:** **7% to 8%** projected from CGHS rate revisions ## B. Geopolitical Disruptions * **Strategic Market Pivot:** Management is mitigating volatility from the **C. S.-Iran conflict** by diversifying into **CIS and African markets**, which are currently exhibiting robust momentum. ## C. Government Scheme Pricing * **Rate Revision Tailwinds:** Anticipated top-line growth is driven by recent CGHS rate adjustments, which are expected to catalyze similar upward revisions across **RGHS** and corporate contracts. * **Realization Timeline:** Initial benefits of the revised pricing are already surfacing, with full financial impact slated to materialize during **Q1 and Q2** of the upcoming fiscal year. --- # 7. Guidance & Outlook ## A. Key Figures * **CAPEX:** **₹160 Cr** FY26 allocation * **Growth Target:** **15%** minimum long-term CAGR for Hospital/Pharma * **Capacity Headroom:** **40% to 50%** upside available on current infrastructure ## B. Revenue & EBITDA Targets * **Profitability Drivers:** Management expects healthy top-line momentum and gross margin expansion driven by strategic cost measures. * **Growth Inflection:** Significant financial acceleration is projected for **Q1 FY27**, with peak performance from **Q2 FY27** following the Gurugram unit’s accreditation. ## C. CAPEX & Cash Flow * **Strategic Reinvestment:** Current year spending is concentrated in high-growth verticals including oncology, robotics, and international expansion. * **Cash Flow Preservation:** Capital intensity is expected to drop sharply from **FY27** onwards as major projects conclude, supporting enhanced free cash flow. ## D. Long-term CAGR Goals * **Operational Pivot:** FY27 is identified as a critical transition year, shifting focus from regulatory groundwork to global market penetration and scaling. * **Innovation Pipeline:** R&D efforts are locked in through **FY 2030**, prioritizing next-generation orthopedic implants and clinical outcome optimization. * **Asset-Light Scaling:** The hospital and pharma segments are positioned to achieve double-digit growth without further heavy investment due to existing capacity.